The NLRP4 antibody targets the nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing protein 4 (NLRP4), a member of the NLR family involved in innate immunity. NLRP4 functions as a regulator of inflammatory signaling pathways, particularly through its role in modulating inflammasome activity and type I interferon (IFN) responses. It contains a pyrin domain (PYD), a central NACHT domain for ATPase activity, and a leucine-rich repeat (LRR) domain, which facilitates protein-protein interactions and pathogen sensing. NLRP4 is known to negatively regulate IFN-β production by interacting with key signaling molecules like RIG-I and MDA5. thereby influencing antiviral defense and autoimmune regulation. Antibodies against NLRP4 are essential tools for studying its expression, localization, and functional mechanisms in immune cells and disease models. They are widely used in techniques such as Western blotting, immunofluorescence, and immunoprecipitation to investigate NLRP4's involvement in pathologies like autoimmune disorders, infections, and cancer. Recent studies also explore NLRP4's potential as a therapeutic target, emphasizing the need for high-specificity antibodies to minimize cross-reactivity with other NLR family members. Commercial NLRP4 antibodies are typically developed in hosts like rabbits or mice, with validation across multiple applications to ensure reliability in experimental settings.